X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
BT-11 (omilancor) is a novel, oral, gut-restricted therapeutic targeting the lanthionine synthetase C-like 2 (LANCL2) pathway which decreases the production of key inflammatory mediators causing ulcerative colitis.
Lead Product(s): Omilancor
Therapeutic Area: Gastroenterology Product Name: BT-11
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
NIMML will utilize its proprietary TITAN-X drug development platform, advanced computational modeling, A.I., and bioinformatics capabilities to implement biomarker-driven approaches in NImmune’s upcoming trials involving its LANCL therapeutics, including BT-11 (omilancor).
Lead Product(s): Omilancor
Therapeutic Area: Gastroenterology Product Name: BT-11
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NImmune Biopharma
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 03, 2023
Details:
BT-11 (omilancor) is a novel, oral, gut-restricted therapeutic targeting the lanthionine synthetase C-like 2 (LANCL2) pathway which decreases the production of key inflammatory mediators causing ulcerative colitis.
Lead Product(s): Omilancor
Therapeutic Area: Gastroenterology Product Name: BT-11
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NImmune Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
Landos Biopharma collaborate with Icahn School of Medicine to conduct a Phase 2 trial of omilancor, a novel, oral, gut-restricted, small-molecule investigational drug that targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway impacting the gastrointestinal tract.
Lead Product(s): Omilancor
Therapeutic Area: Gastroenterology Product Name: BT-11
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Icahn School of Medicine
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 20, 2021
Details:
Discovered using Landos proprietary LANCE® Advanced A.I. platform, omilancor is a novel, oral, gut-restricted small molecule investigational drug that targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway impacting the gastrointestinal tract.
Lead Product(s): Omilancor
Therapeutic Area: Gastroenterology Product Name: BT-11
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2021
Details:
LianBio will receive exclusive rights to develop and commercialize BT-11 and NX-13 in Greater China, South Korea, Singapore, Thailand, Vietnam, Myanmar, Cambodia, Indonesia, and the Philippines.
Lead Product(s): Omilancor
Therapeutic Area: Gastroenterology Product Name: BT-11
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: LianBio
Deal Size: $218.0 million Upfront Cash: $18.0 million
Deal Type: Collaboration May 17, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
